- Companies
- Superluminal Medicines
Superluminal Medicines Funding, Investors & Competitors
Superluminal Medicines has raised $219M across 3 funding rounds, most recently a $66M Series B in September 2026.
About Superluminal Medicines
Superluminal Medicines is a Boston-based biotech firm using generative AI and machine learning to design novel drug candidates. Its platform combines proprietary datasets on biology and chemistry with high-throughput simulations to produce optimized compounds for therapeutic targets. The company targets oncology and rare diseases, accelerating discovery from target identification to preclinical testing.
Founded
2022
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Licensing, Subscription
Superluminal Medicines Funding History
Superluminal Medicines has raised a total of $219M across 3 funding rounds.
Superluminal Medicines' first fundraising round was a $33M seed round in August 2023. The most recent completed round was a $66M Series B in September 2026.
Superluminal Medicines funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Sep 2026 | Series B | BVF Partners (lead); NVIDIA; Cooley; Catalio Capital Management; Eli Lilly; Deep Track Capital; RA Capital Management; Gaingels; Insight Partners; Perceptive Advisors | $66M | BVF Partners led Superluminal Medicines’ oversubscribed $60 million Series B financing, with participation from Deep Track Capital, Perceptive Advisors, and existing backers including RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels. The financing was announced on September 3, 2026 and was described as a closed Series B round. The capital is intended to advance Superluminal’s lead program for rare genetic forms of obesity into the clinic, with the company saying it expects to support a first Phase 1 clinical trial by the end of 2026 and expand its GPCR-focused discovery platform. Superluminal is a Boston biotechnology company that uses AI, machine learning, protein dynamics, and structural biology to discover drugs against difficult GPCR targets and is developing therapies for obesity and other genetic diseases. |
| Sep 2024 | Series A | RA Capital Management (lead); NVentures; Cooley; Catalio Capital Management; Eli Lilly; Gaingels; Insight Partners | $120M | Superluminal Medicines, Inc., a Boston-based biotech known as 'The Membrane Company,' leverages generative biology, chemistry, and machine learning to accelerate the creation of medicines targeting membrane receptors like G protein-coupled receptors (GPCRs), ion channels, and transporters. The company's discovery engine features advanced pharmacokinetic and toxicology in silico predictions, enabling rapid generation of candidate-ready small molecule compounds with high selectivity for specific protein structural changes. Its proprietary pipeline validates the platform through programs focused on high-value GPCR targets, with plans to advance the lead program into clinical development. On September 9, 2024, Superluminal closed a $120 million Series A funding round led by RA Capital Management, with participation from existing investors Insight Partners, NVentures (NVIDIA's venture arm), and Gaingels, plus new investors Catalio Capital Management, Eli Lilly and Company, and Cooley LLP. Diamantis Xylas, MD from Catalio, joined the board. This follows a $33 million seed round in August 2023, also led by RA Capital with Insight Partners, NVIDIA, and Gaingels. The Series A proceeds will fund clinical progression of lead programs and expansion of the small molecule pipeline targeting challenging GPCRs. Superluminal operates from Eli Lilly's incubator space, Lilly Gateway Labs, in Boston and benefits from a strong investor network emphasizing evidence-based life sciences investing. RA Capital highlighted the company's rapid progress on difficult drug targets. The platform integrates deep biology and chemistry expertise with machine learning and proprietary big data infrastructure to revolutionize pharmaceutical R&D speed and accuracy, positioning Superluminal to deliver transformative therapies faster. |
| Aug 2023 | Seed | RA Capital Management (lead); NVIDIA; Gaingels; Insight Partners | $33M | Superluminal Medicines, a Boston-based biotechnology company, launched on August 28, 2023, with a $33 million seed funding round led by RA Capital Management, with participation from Insight Partners, NVIDIA (via NVentures), and Gaingels. The company combines generative biology, chemistry, and machine learning to accelerate small molecule drug discovery, particularly targeting high-value G protein-coupled receptors (GPCRs), which represent major drug targets underlying about one-third of approved medicines. Funds from the seed round support advancement of its pipeline, with a lead program candidate expected in the near term, validating its platform's speed in generating candidate-ready compounds. Superluminal was co-founded by Ajay Yekkirala, a former RA Capital executive, and Cony D’Cruz, former Evotec executive, emphasizing deep biology expertise with AI to explore protein conformations for challenging membrane targets like GPCRs. The $33 million seed is notably large compared to typical seed rounds of $5-9 million across sectors. The company's approach aims to revolutionize medicine creation speed and accuracy for membrane receptors critical to cell signaling. In September 2024, Superluminal closed a $120 million Series A extension led by RA Capital, with participation from seed investors Insight Partners, NVentures, and Gaingels, plus new investors Catalio Capital Management and Eli Lilly. Proceeds fund clinical development of lead programs and pipeline expansion. |
Who has invested in Superluminal Medicines?
11 investors have backed Superluminal Medicines across its funding rounds, including Insight Partners, Gaingels, RA Capital Management, NVIDIA, Eli Lilly and Catalio Capital Management.
Lead investors include BVF Partners and RA Capital Management.
Superluminal Medicines Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Lead | Aug 2023 | ||
| 3 | Participant | Aug 2023 | ||
| 3 | Participant | Aug 2023 | ||
| 2 | Participant | Aug 2023 | ||
| 2 | Participant | Sep 2024 | ||
| 2 | Participant | Sep 2024 | ||
| 2 | Participant | Sep 2024 | ||
| 1 | Participant | Sep 2024 | ||
| 1 | Participant | Sep 2026 | ||
This data is available for Pro users. Sign up to see all 11 Superluminal Medicines investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialSuperluminal Medicines Competitors
Superluminal Medicines competitors include listed companies like SAP and Snowflake, and private ones like Astromech, Chai Discovery, Anthropic and OpenAI.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $3.8B | - | ||
| Private | $48M | - | $3.8B | - | ||
| Private | $47B | - | $965B | 20.5x | ||
| Private | $25B | - | $852B | 34.1x | ||
| Publicly listed | $42B | $13B | $248B | 5.4x | ||
| Publicly listed | $4.7B | ($1.3B) | $119B | 21.0x |
Superluminal Medicines Public Comps
Superluminal Medicines is still privately-owned, but its public comps include Eli Lilly, Johnson & Johnson, AbbVie, Merck, Roche, Novartis, AstraZeneca, CrowdStrike, SAP and Amgen.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $65B | $28B | 16.5x | 13.1x | 38.7x | 27.0x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $61B | $17B | 8.7x | 8.1x | 30.6x | 17.6x | |||
| $65B | $28B | 6.3x | 6.2x | 14.7x | 21.0x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $57B | $22B | 5.5x | 5.5x | 14.2x | 13.3x | |||
| $59B | $19B | 4.8x | 4.5x | 14.6x | 12.7x | |||
| $4.8B | ($12M) | 51.4x | 44.5x | (19816.2x) | 151.0x | |||
This data is available for Pro users. Sign up to see all Superluminal Medicines competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Superluminal Medicines
| When was Superluminal Medicines founded? | Superluminal Medicines was founded in 2022. |
| Where is Superluminal Medicines headquartered? | Superluminal Medicines is headquartered in Boston, MA, United States. |
| Is Superluminal Medicines publicly listed? | No, Superluminal Medicines is a private, VC-backed company. |
| How much funding has Superluminal Medicines raised? | Superluminal Medicines has raised $219M across 3 funding rounds. |
| What was Superluminal Medicines' last funding round? | Superluminal Medicines' last funding round was a $66M Series B in September 2026, led by BVF Partners. |
| Who are Superluminal Medicines' investors? | Superluminal Medicines' investors include RA Capital Management, Gaingels, Insight Partners, NVIDIA, Cooley, Catalio Capital Management, Eli Lilly, NVentures, Deep Track Capital, BVF Partners and 1 other. |
| Which companies are comparable to Superluminal Medicines? | Companies comparable to Superluminal Medicines include Astromech, Chai Discovery, Anthropic, OpenAI, SAP and Snowflake. |
See companies similar to Superluminal Medicines
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




